A House investigative panel plans to hold a new hearing to grill the drug maker behind a 400 percent price hike for the life-saving allergy drug EpiPen.
The House Oversight Committee’s Sept. 21 hearing will include testimony from Mylan CEO Heather Bresch on the high price tag of $600 for EpiPens. She later lowered the price for some patients after public outcry.
“There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens,” Ranking Member Rep. Elijah Cummings, D-Md., said in a statement.
It remains unclear who else will attend the hearing. Cummings hopes infamous pharma CEO Martin Shkreli will attend.
“I am excited about possibly bringing Shkreli back, hopefully he provides some testimony this time,” Cummings said during an unrelated hearing on Obamacare premiums Wednesday. Cummings was referring to Shkreli’s initial appearance before the committee this year in which the former CEO responsible for raising the price of an antimalarial drug refused to testify because he is facing federal securities charges for an unrelated matter.
However, Shkreli’s appearance is not a done deal.
“I’m not sure ‘pharma boy’ is coming back,” said Rep. Jason Chaffetz, R-Utah, the committee chairman.
